AIMEE FINJAP: Open Payments
NPI 1104512847 · REYNOLDSBURG, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 24 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $402 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $95 |
| ABBVIE INC. | 3 | $63 |
| Lundbeck LLC | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Abbott Laboratories | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
Products named: CAPLYTA, GEMTESA, REXULTI, VRAYLAR, KEVEYIS, FREESTYLE LIBRE 3, XIFAXAN, UZEDY.
Industry payments across OH — which companies pay providers there.
